Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Inflammatory Breast Cancer (IBC) is a distinct clinical subtype of locally advanced breast cancer, with a particularly aggressive behavior and poor prognosis. Clinically, IBC typically presents with rapidly progressive breast warmth, erythema and edema [1]. It is now well established that adjuvant systemic therapy improves survival in patients with early-stage breast cancer [2]. Breast cancer is highly curable if diagnosed at early stage. Recent progress in diagnosis and therapy has increased the survival of women in estrogen-dependent breast cancer. However, despite advances in multidisciplinary treatment, the prognosis of IBC is less favorable than of non-IBC, with a 3-year survival of about 40% [3,4]. Activation of NF-κB in inflammatory breast cancer is associated with loss of Estrogen Receptor (ER) expression, indicating a potential crosstalk between NF-κB and ER. It has been shown that NF-κB activation is not exclusively limited to IBC but more general to ERα- breast tumors. Copeland RL Jr, Kanaan YM (2012) Inflammatory Breast Cancer is Associated with Hyperactivated Mitogen Activated Kinase. J Autacoids 1:e114. https://www.omicsonline.org/inflammatory-breast-cancer-is-associated-with-hyperactivated-mitogen-activated-kinase-2161-0479.1000e114.php?aid=6185
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi